# Sensor Augmented Pump Therapy Versus Multiple Daily Injection Therapy

Study · id `cardio:ct-nct01921322` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01921322](<https://clinicaltrials.gov/study/NCT01921322>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01921322

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 118 participants.

## Technical summary

Registry record NCT01921322. Randomized; no masking; primary purpose treatment. Start 2013-04 (registry gives no type); primary completion 2015-05 (actual). Results posted on 2017-07-06.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 118 participants (enrolled count; ClinicalTrials.gov record NCT01921322, source copy `cardio:ctgov-nct01921322-2017-07-06`, retrieved 2026-10-26)
- Start date: 2013-04 (registry gives no type) (ClinicalTrials.gov record NCT01921322, source copy `cardio:ctgov-nct01921322-2017-07-06`, retrieved 2026-10-26)
- Primary completion: 2015-05 (actual) (ClinicalTrials.gov record NCT01921322, source copy `cardio:ctgov-nct01921322-2017-07-06`, retrieved 2026-10-26)
- Completion: 2015-05 (actual) (ClinicalTrials.gov record NCT01921322, source copy `cardio:ctgov-nct01921322-2017-07-06`, retrieved 2026-10-26)
- Results first posted: 2017-07-06 (ClinicalTrials.gov record NCT01921322, source copy `cardio:ctgov-nct01921322-2017-07-06`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT01921322, source copy `cardio:ctgov-nct01921322-2017-07-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01921322-2017-07-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Sensor Augmented Pump Therapy Versus Multiple Daily Injection Therapy
- Condition: Type 2 Diabetes
- Intervention (Device): Pump
- Intervention (Other): CGMS Gold
- Lead sponsor: Medtronic MiniMed, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Medtronic MiniMed, Inc. (`cardio:org-medtronic-minimed-inc`)

## Provenance

Content hash: f5e9a2cd76490025b5a8d55d188dc8a8564c0ba0b20b0cb41ba190aeb2a7fd65
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
